BPIFB4 and diabetic cardiomyopathy: In concert with the beneficial effect of SDF-1 on heart and the ability of BPIFB4 in promoting the SDF-1 expression on monocytes and in db/db mice heart, LAV-BPIFB4 might be considered as an immunoregulatory driver in CVDs (i.e. diabetic cardiomyopathy) considering its influence on SDF-1 expression that in turn could exhibit its protective role.